HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am.
More information
Skip to Main content
Skip to Navigation
Toggle navigation
Sign in
Sign in
Sign in with ORCID
se connecter avec Fédération
Create account
Forgot your password?
Have you forgotten your login?
fr
en
Home
Browse latest submissions
Browse by search
Browse by author
About CALYM
Home
Last publications
Fabienne Desmots, Mikael Roussel, Céline Pangault, Francisco Llamas-Gutierrez, Cedric Pastoret, et al.. Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma. Clinical Cancer Research, American Association for Cancer Research, 2019, 25 (2), pp.735-746. ⟨10.1158/1078-0432.CCR-18-1153⟩. ⟨hal-01952302⟩
Coralie Hoareau-Aveilla, Cathy Quelen, Annabelle Congras, Nina Caillet, Delphine Labourdette, et al.. MiR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells.. Haematologica, Ferrata Storti Foundation, 2019, 104 (2), pp.347-359. ⟨10.3324/haematol.2018.195131⟩. ⟨hal-01951558⟩
Hadjer Miloudi, Karen Leroy, Fabrice Jardin, Brigitte Sola. STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma. Cellular Signalling, Elsevier, 2018, 46, pp.76-82. ⟨10.1016/j.cellsig.2018.02.016⟩. ⟨hal-01725066⟩
Francesca Petraglia, Abhishek Singh, Vincenzo Carafa, Angela Nebbioso, Mariarosaria Conte, et al.. Combined HAT/EZH2 modulation leads to cancer-selective cell death. Oncotarget, Impact journals, 2018, 9 (39), pp.25630-25646. ⟨10.18632/oncotarget.25428⟩. ⟨hal-01873834⟩
Aude Le Roy, Thomas Prebet, Remy Castellano, Armelle Goubard, Florence Riccardi, et al.. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. Frontiers in Immunology, Frontiers, 2018, 9, pp.977. ⟨10.3389/fimmu.2018.00977⟩. ⟨hal-01791593⟩
Sarah Huet, Bruno Tesson, Jean-Philippe Jais, Andrew Feldman, Laura Magnano, et al.. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncology, Elsevier, 2018, 19 (4), pp.549 - 561. ⟨10.1016/S1470-2045(18)30102-5⟩. ⟨hal-01788996⟩
Alexandra Frelau, Marc Pracht, Samuel Le Sourd, Alexandra Lespagnol, Romain Corre, et al.. Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns. Bulletin du Cancer, John Libbey Eurotext, 2018, ⟨10.1016/j.bulcan.2017.10.031⟩. ⟨hal-01815717⟩
Vaclav Janovec, Besma Aouar, Albert Font-Haro, Tomas Hofman, Katerina Trejbalova, et al.. The MEK1/2-ERK Pathway Inhibits Type I IFN Production in Plasmacytoid Dendritic Cells. Frontiers in Immunology, Frontiers, 2018, 9, pp.364. ⟨10.3389/fimmu.2018.00364⟩. ⟨hal-01772995⟩
Shamzah Araf, Jun Wang, Koorosh Korfi, Céline Pangault, Eleni Kotsiou, et al.. Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2018, 32 (5), pp.1258-1263. ⟨10.1038/s41375-018-0043-y⟩. ⟨hal-01815695⟩
Thierry Lamy, Gandhi Damaj, Pierre Soubeyran, Emmanuel Gyan, Guillaume Cartron, et al.. R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL). Blood, American Society of Hematology, 2018, 131 (2), pp.174-181. ⟨10.1182/blood-2017-07-793984⟩. ⟨hal-01635792⟩